Krensavage Asset Management, LLC
NEW YORK, NY · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 17, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$265.4M2026 Q3
Positions20
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.88.1%
What Changed This Quarter?
Top Holdings
JAZZ
Jazz Pharmaceuticals
14.6%
ENTA
Enanta Pharmaceuticals
14.2%
UTHR
United Therapeutics
13.5%
BMRN
Biomarin Pharmaceutical
11.9%
ABT
Abbott Laboratories
7.4%
EXEL
Exelixis
6.6%
RARE
Ultragenyx Pharmaceutical
6.5%
SUPN
Supernus
5.7%
New / Increased
3 new · 4 increased
ANIPNEW
Ani Pharmaceuticals
0.4%
ACADNEW
Acadia Pharmaceuticals
0.3%
ZTSNEW
Zoetis
0.3%
RARE
Ultragenyx Pharmaceutical In
6.5%
+191.9%
ARDX
Ardelyx
2.3%
+239.6%
SUPN
Supernus Pharmaceuticals
5.7%
+24.9%
SNY
Sanofi-Adr
5.2%
+3.1%
Reduced / Exited
3 reduced · 1 sold out
EXEL
Exelixis
6.6%
-19.2%
UTHR
United Therapeutics
13.5%
-4.3%
EOLS
Evolus
0.2%
-63.3%
REGNEXIT
Regeneron Pharmaceuticals
1.4%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.